Clinical Trials for Medical Devices and Drugs Relating to COVID-19 Regulations, SOR/2022-18
Section 35
Records
Cite as Clinical Trials for Medical Devices and Drugs Relating to COVID-19 Regulations, SOR/2022-18, s. 35 · current to July 24, 2025 · regulation last amended February 27, 2022
Statute Watch
Get an alert when a bill in Parliament would change this section, and every time it moves.
The text
(1) A holder of a COVID-19 drug authorization must record, handle and store all information in respect of the clinical trial for which the authorization has been issued in a manner that allows for the complete and accurate reporting as well as the interpretation and verification of the information.
(2) The holder of the authorization must maintain complete and accurate records, which include the following, in respect of a COVID-19 drug for which the authorization has been issued in order to establish that the clinical trial is conducted in accordance with good clinical practices and these Regulations:
(a) the information and material referred to in paragraphs 20(2)(e) to (k);
(b) records respecting each change made to the information and material referred to in paragraph (a), the rationale for each change and documentation that supports each change;
(c) records respecting all adverse events in respect of the drug that have occurred inside or outside Canada, including the indication for use and the dosage form of the drug at the time of the adverse event;
(d) in respect of a drug that meets the requirements of paragraphs 27(a) to (c), records respecting any serious unexpected adverse drug reaction that has occurred inside or outside Canada;
(e) records respecting the enrolment of clinical trial subjects, including information that allows all subjects to be identified and contacted in the event that the sale of the drug may endanger the health of the subjects or other persons;
(f) records respecting the shipment, receipt, disposition, return and destruction of the drug;
(g) for each clinical trial site, an undertaking, signed and dated by the qualified investigator prior to the commencement of their responsibilities in respect of the clinical trial stating that
(i) the qualified investigator will conduct the clinical trial in accordance with good clinical practices, and
(ii) the qualified investigator will immediately, on discontinuance of the clinical trial, in whole or in part, by the holder, inform both the clinical trial subjects and the research ethics board of the discontinuance, provide them with the reasons for the discontinuance and advise them, in writing, of any potential risks to the health of subjects or other persons;
(h) for each clinical trial site, a copy of the protocol, informed consent form and any amendment to the protocol or informed consent form that have been approved by a research ethics board for that site; and
(i) for each clinical trial site, an attestation, signed and dated by a research ethics board, stating that it has reviewed and approved the protocol and informed consent form and that the board carries out its functions in a manner consistent with good clinical practices.
(3) The holder — or former holder, in the case of an authorization that has been revoked in whole — of the authorization must retain all records referred to in subsection (2) for a period of 15 years.
Read the Clinical Trials for Medical Devices and Drugs Relating to COVID-19 Regulations on the Justice Laws Website ↗
Made under Food and Drugs Act, R.S.C. 1985, c. F-27; Patent Act, R.S.C. 1985, c. P-4.
Bills in Parliament that would change this section 0
No bill we hold would amend or repeal this section.